<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32300346</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.</ArticleTitle><Pagination><StartPage>546</StartPage><MedlinePgn>546</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">546</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.00546</ELocationID><Abstract><AbstractText>Dengue is an emerging mosquito-borne disease, and the use of prophylactic vaccines is still limited. We previously developed a tetravalent dengue vaccine (rMV-TDV) by a recombinant measles virus (MV) vector expressing envelope protein domain III (ED3). In this study, we used dengue-susceptible AG129 mice to evaluate the protective and/or pathogenic immune responses induced by rMV-TDV. Consistent with the previous study, rMV-TDV-immunized mice developed a significant neutralizing antibody response against all serotypes of DENV, as well as a significant IFN-&#x3b3; response biased to DENV-3, compared to the vector controls. We further demonstrated that this DENV-3-specific IFN-&#x3b3; response was dominated by one CD4<sup>+</sup> T-cell epitope located in E<sub>349-363</sub>. After DENV-2 challenge, rMV-TDV-immunized mice showed a significantly lower viremia and no inflammatory cytokine increase compared to the vector controls, which had an ~100 times higher viremia and a significant increase in IFN-&#x3b3; and TNF-&#x3b1;. As a correlate of protection, a robust memory IFN-&#x3b3; response specific to DENV-2 was boosted in rMV-TDV-immunized mice after challenge. This result suggested that pre-existing DENV-3-dominated T-cell responses did not cross-react, but a DENV-2-specific IFN-&#x3b3; response, which was undetectable during immunization, was recalled. Interestingly, this recalled T-cell response recognized the epitope in the same position as the E<sub>349-363</sub> but in the DENV-2 serotype. This result suggested that immunodomination occurred in the CD4<sup>+</sup> T-cell epitopes between dengue serotypes after rMV-TDV vaccination and resulted in a DENV-3-dominated CD4<sup>+</sup> T-cell response. Although the significant increase in IgG against both DENV-2 and -3 suggested that cross-reactive antibody responses were boosted, the increased neutralizing antibodies and IgG avidity still remained DENV-2 specific, consistent with the serotype-specific T cell response post challenge. Our data reveal that immunodomination caused a biased T-cell response to one of the dengue serotypes after tetravalent dengue vaccination and highlight the roles of cross-reactive T cells in dengue protection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Lin, Chen, Hsiao, Yan, Chiang, Chen, Hu, Wu and Pan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Tsung-Han</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Yu-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Jia-Ying</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chen-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Yu</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hui-Mei</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Szu-Hsien</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016056" MajorTopicYN="N">Immunodominant Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008459" MajorTopicYN="N">Measles virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AG129 mice</Keyword><Keyword MajorTopicYN="N">dengue</Keyword><Keyword MajorTopicYN="N">dengue vaccine</Keyword><Keyword MajorTopicYN="N">envelope protein</Keyword><Keyword MajorTopicYN="N">immunodominance</Keyword><Keyword MajorTopicYN="N">recombinant measles virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32300346</ArticleId><ArticleId IdType="pmc">PMC7145397</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.00546</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Hum Vaccin. (2011) 7:674&#x2013;84. 10.4161/hv.7.6.14985</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.7.6.14985</ArticleId><ArticleId IdType="pubmed">21508679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. . The global distribution and burden of dengue. Nature. (2013) 496:504&#x2013;7. 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. (2016) 16:935&#x2013;41. 10.1016/S1473-3099(16)00146-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)00146-8</ArticleId><ArticleId IdType="pubmed">27091092</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. . The global burden of dengue: an analysis from the Global Burden of Disease Study (2013). Lancet Infect Dis. (2016) 16:712&#x2013;23. 10.1016/S1473-3099(16)00026-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)00026-8</ArticleId><ArticleId IdType="pmc">PMC5012511</ArticleId><ArticleId IdType="pubmed">26874619</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. World Health Organization; (2009).</Citation></Reference><Reference><Citation>Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. (2011) 3:2374&#x2013;95. 10.3390/v3122374</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3122374</ArticleId><ArticleId IdType="pmc">PMC3280510</ArticleId><ArticleId IdType="pubmed">22355444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. T lymphocyte responses to heterologous secondary dengue virus infections. Ann N Y Acad Sci. (1171) Suppl. (2009) 1:E36&#x2013;41. 10.1111/j.1749-6632.2009.05055.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05055.x</ArticleId><ArticleId IdType="pubmed">19751400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, et al. . Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis. (2004) 189:221&#x2013;32. 10.1086/380762</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/380762</ArticleId><ArticleId IdType="pubmed">14722886</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. (1977) 265:739&#x2013;41. 10.1038/265739a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/265739a0</ArticleId><ArticleId IdType="pubmed">404559</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. (2011) 29:587&#x2013;619. 10.1146/annurev-immunol-031210-101315</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101315</ArticleId><ArticleId IdType="pubmed">21219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. . Cross-reacting antibodies enhance dengue virus infection in humans. Science. (2010) 328:745&#x2013;8. 10.1126/science.1185181</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, et al. . Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology. (2008) 376:429&#x2013;35. 10.1016/j.virol.2008.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.03.028</ArticleId><ArticleId IdType="pmc">PMC2546568</ArticleId><ArticleId IdType="pubmed">18452966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. (2010) 7:128&#x2013;39. 10.1016/j.chom.2010.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.01.004</ArticleId><ArticleId IdType="pmc">PMC2824513</ArticleId><ArticleId IdType="pubmed">20153282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL, Ennis FA. Immunopathogenesis of dengue hemorrhagic fever. Virology. (1999) 257:1&#x2013;6. 10.1006/viro.1999.9656</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1999.9656</ArticleId><ArticleId IdType="pubmed">10208914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. (2011) 11:532&#x2013;43. 10.1038/nri3014</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3014</ArticleId><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Falgout B, Hanley KA, Blaney JE, Jr, Markoff L, et al. . A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol. (2003) 77:1653&#x2013;7. 10.1128/JVI.77.2.1653-1657.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.2.1653-1657.2003</ArticleId><ArticleId IdType="pmc">PMC140839</ArticleId><ArticleId IdType="pubmed">12502885</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. . Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. (2000) 74:5477&#x2013;85. 10.1128/JVI.74.12.5477-5485.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.12.5477-5485.2000</ArticleId><ArticleId IdType="pmc">PMC112032</ArticleId><ArticleId IdType="pubmed">10823852</ArticleId></ArticleIdList></Reference><Reference><Citation>Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg. (2003) 68:469&#x2013;76. 10.4269/ajtmh.2003.68.469</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2003.68.469</ArticleId><ArticleId IdType="pubmed">12875299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, et al. . A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. (2006) 24:3165&#x2013;71. 10.1016/j.vaccine.2006.01.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.036</ArticleId><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, et al. . Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg. (2003) 69:17&#x2013;23. 10.4269/ajtmh.2003.69.17</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2003.69.17</ArticleId><ArticleId IdType="pubmed">14740951</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, et al. . Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine. (2011) 29:960&#x2013;8. 10.1016/j.vaccine.2010.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.11.050</ArticleId><ArticleId IdType="pubmed">21111785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. . Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. (2015) 373:1195&#x2013;206. 10.1056/NEJMoa1506223</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506223</ArticleId><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, et al. . Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. Hum Vaccin Immunother. (2019) 15:2090&#x2013;105. 10.1080/21645515.2019.1581536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1581536</ArticleId><ArticleId IdType="pmc">PMC6773406</ArticleId><ArticleId IdType="pubmed">30829100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. . Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. (2012) 380:1559&#x2013;67. 10.1016/S0140-6736(12)61428-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61428-7</ArticleId><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. (2014) 384:1358&#x2013;65. 10.1016/S0140-6736(14)61060-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. . Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg. (2009) 80:302&#x2013;11. 10.4269/ajtmh.2009.80.302</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2009.80.302</ArticleId><ArticleId IdType="pubmed">19190230</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity. (2000) 12:83&#x2013;93. 10.1016/S1074-7613(00)80161-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80161-2</ArticleId><ArticleId IdType="pubmed">10661408</ArticleId></ArticleIdList></Reference><Reference><Citation>La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, Chen W, et al. . A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci USA. (2006) 103:994&#x2013;9. 10.1073/pnas.0510429103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0510429103</ArticleId><ArticleId IdType="pmc">PMC1348014</ArticleId><ArticleId IdType="pubmed">16418289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, Busch DH, et al. . Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med. (2007) 204:2187&#x2013;98. 10.1084/jem.20070489</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070489</ArticleId><ArticleId IdType="pmc">PMC2118691</ArticleId><ArticleId IdType="pubmed">17709425</ArticleId></ArticleIdList></Reference><Reference><Citation>Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, Doherty PC, et al. . Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci USA. (2003) 100:7235&#x2013;40. 10.1073/pnas.1232449100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1232449100</ArticleId><ArticleId IdType="pmc">PMC165859</ArticleId><ArticleId IdType="pubmed">12775762</ArticleId></ArticleIdList></Reference><Reference><Citation>Im EJ, Hong JP, Roshorm Y, Bridgeman A, Letourneau S, Liljestrom P, et al. . Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog. (2011) 7:e1002041. 10.1371/journal.ppat.1002041</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002041</ArticleId><ArticleId IdType="pmc">PMC3098219</ArticleId><ArticleId IdType="pubmed">21625575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauron EJ, Yang L, Elliott JI, Gainey MD, Fremont DH, Yokoyama WM. Cross-priming induces immunodomination in the presence of viral MHC class I inhibition. PLoS Pathog. (2018) 14:e1006883. 10.1371/journal.ppat.1006883</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006883</ArticleId><ArticleId IdType="pmc">PMC5812664</ArticleId><ArticleId IdType="pubmed">29444189</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Background Paer On Dengue Vaccines. WHO; (2016).</Citation></Reference><Reference><Citation>Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. (2016) 14:45&#x2013;54. 10.1038/nrmicro.2015.2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2015.2</ArticleId><ArticleId IdType="pubmed">26639777</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. (2007) 5:518&#x2013;28. 10.1038/nrmicro1690</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1690</ArticleId><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau L, Green AM, Balmaseda A, Harris E. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity. J Clin Virol. (2015) 69:63&#x2013;7. 10.1016/j.jcv.2015.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2015.06.003</ArticleId><ArticleId IdType="pmc">PMC4978614</ArticleId><ArticleId IdType="pubmed">26209381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, et al. . IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science. (2017) 355:395&#x2013;8. 10.1126/science.aai8128</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aai8128</ArticleId><ArticleId IdType="pmc">PMC5557095</ArticleId><ArticleId IdType="pubmed">28126818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. . Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. (2011) 203:1282&#x2013;91. 10.1093/infdis/jir012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir012</ArticleId><ArticleId IdType="pmc">PMC3069729</ArticleId><ArticleId IdType="pubmed">21335561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, et al. . CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol. (2010) 185:5405&#x2013;16. 10.4049/jimmunol.1001709</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001709</ArticleId><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. (2013) 9:e1003723. 10.1371/journal.ppat.1003723</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003723</ArticleId><ArticleId IdType="pmc">PMC3814346</ArticleId><ArticleId IdType="pubmed">24204271</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol. (2014) 5:93. 10.3389/fimmu.2014.00093</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00093</ArticleId><ArticleId IdType="pmc">PMC3945531</ArticleId><ArticleId IdType="pubmed">24639680</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. (2006) 4:900&#x2013;8. 10.1038/nrmicro1550</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1550</ArticleId><ArticleId IdType="pmc">PMC7097605</ArticleId><ArticleId IdType="pubmed">17088933</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi A, Toriniwa H, Komiya T, Nakayama T. Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus. PLoS ONE. (2016) 11:e0150213. 10.1371/journal.pone.0150213</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150213</ArticleId><ArticleId IdType="pmc">PMC4773129</ArticleId><ArticleId IdType="pubmed">26930411</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Lucas-Hourani M, Moris A, Frenkiel M-P, Combredet C, F&#xe9;vrier M, et al. . Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis. (2007) 1:e96. 10.1371/journal.pntd.0000096</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0000096</ArticleId><ArticleId IdType="pmc">PMC2154386</ArticleId><ArticleId IdType="pubmed">18160988</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurnberger C, Bodmer BS, Fiedler AH, Gabriel G, Muhlebach MD. A measles virus-based vaccine candidate mediates protection against zika virus in an allogeneic mouse pregnancy model. J Virol. (2019) 93:e01485-01418. 10.1128/JVI.01485-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01485-18</ArticleId><ArticleId IdType="pmc">PMC6340036</ArticleId><ArticleId IdType="pubmed">30429338</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, et al. . A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. (2013) 31:3718&#x2013;25. 10.1016/j.vaccine.2013.05.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.086</ArticleId><ArticleId IdType="pubmed">23742993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu HM, Chen HW, Hsiao YJ, Wu SH, Chung HH, Hsieh CH, et al. . The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother. (2016) 12:1678&#x2013;89. 10.1080/21645515.2016.1143576</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1143576</ArticleId><ArticleId IdType="pmc">PMC4964840</ArticleId><ArticleId IdType="pubmed">26901482</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, et al. . Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine. (2012) 30:1513&#x2013;20. 10.1016/j.vaccine.2011.11.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.072</ArticleId><ArticleId IdType="pmc">PMC4592107</ArticleId><ArticleId IdType="pubmed">22178727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med. (2012) 209:1391&#x2013;5. 10.1084/jem.20121517</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121517</ArticleId><ArticleId IdType="pmc">PMC3420330</ArticleId><ArticleId IdType="pubmed">22851641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. . Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol. (2013) 87:2693&#x2013;706. 10.1128/JVI.02675-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02675-12</ArticleId><ArticleId IdType="pmc">PMC3571409</ArticleId><ArticleId IdType="pubmed">23255803</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Suleyman OM, Ortega-Prieto AM, Skelton JK, Bonnesoeur P, Blohm A, et al. . T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other Flaviviruses. Sci Rep. (2018) 8:672. 10.1038/s41598-017-18781-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18781-1</ArticleId><ArticleId IdType="pmc">PMC5766511</ArticleId><ArticleId IdType="pubmed">29330423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. (2009) 392:103&#x2013;13. 10.1016/j.virol.2009.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine. (2005) 23:3469&#x2013;76. 10.1016/j.vaccine.2004.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.12.028</ArticleId><ArticleId IdType="pubmed">15837370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, L&#xf3;pez C, et al. . Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. (2008) 80:194&#x2013;9. 10.1016/j.antiviral.2008.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.06.005</ArticleId><ArticleId IdType="pubmed">18602424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Pan CH, Hsieh CH, Tsai JP, Chen MY, Liu HH, et al. . Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis. (2013) 7:e2432. 10.1371/journal.pntd.0002432</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002432</ArticleId><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, et al. . A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol. (2013) 158:1523&#x2013;31. 10.1007/s00705-013-1639-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-013-1639-1</ArticleId><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Huang MH, Hsieh CH, Chen MY, Liu HH, Tsai JP, et al. . Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis. (2012) 6:e1645. 10.1371/journal.pntd.0001645</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001645</ArticleId><ArticleId IdType="pmc">PMC3352863</ArticleId><ArticleId IdType="pubmed">22616020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Hsieh CH, Chen MY, Tsai JP, Liu HH, Liu SJ, et al. . Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine. (2014) 32:1346&#x2013;1353. 10.1016/j.vaccine.2014.01.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.01.041</ArticleId><ArticleId IdType="pubmed">24486311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Hu HM, Wu SH, Chiang CY, Hsiao YJ, Wu CK, et al. . The immunodominance change and protection of CD4+ T-cell responses elicited by an envelope protein domain III-based tetravalent dengue vaccine in mice. PLoS ONE. (2015) 10:e0145717. 10.1371/journal.pone.0145717</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0145717</ArticleId><ArticleId IdType="pmc">PMC4695087</ArticleId><ArticleId IdType="pubmed">26714037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LC, Flesch IE, Tscharke DC. Immunodomination during peripheral vaccinia virus infection. PLoS Pathog. (2013) 9:e1003329. 10.1371/journal.ppat.1003329</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003329</ArticleId><ArticleId IdType="pmc">PMC3635974</ArticleId><ArticleId IdType="pubmed">23633956</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol. (2014) 88:11383&#x2013;94. 10.1128/JVI.01108-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01108-14</ArticleId><ArticleId IdType="pmc">PMC4178794</ArticleId><ArticleId IdType="pubmed">25056881</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, et al. . HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+ T-cell responses. J Infect Dis. (2016) 214:1117&#x2013;24. 10.1093/infdis/jiw309</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw309</ArticleId><ArticleId IdType="pmc">PMC5021234</ArticleId><ArticleId IdType="pubmed">27443615</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Grifoni A, Sette A, Weiskopf D. Human T cell response to dengue virus infection. Front Immunol. (2019) 10:2125. 10.3389/fimmu.2019.02125</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02125</ArticleId><ArticleId IdType="pmc">PMC6737489</ArticleId><ArticleId IdType="pubmed">31552052</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. . Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA. (2013) 110:E2046&#x2013;53. 10.1073/pnas.1305227110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1305227110</ArticleId><ArticleId IdType="pmc">PMC3670335</ArticleId><ArticleId IdType="pubmed">23580623</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, et al. . Human CD4(+) T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol. (2017) 91:e02147-02116. 10.1128/JVI.02147-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02147-16</ArticleId><ArticleId IdType="pmc">PMC5309943</ArticleId><ArticleId IdType="pubmed">27974563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S. CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol. (2015) 89:6494&#x2013;505. 10.1128/JVI.00036-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00036-15</ArticleId><ArticleId IdType="pmc">PMC4474296</ArticleId><ArticleId IdType="pubmed">25855749</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol. (1995) 69:4792&#x2013;6. 10.1128/JVI.69.8.4792-4796.1995</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.8.4792-4796.1995</ArticleId><ArticleId IdType="pmc">PMC189290</ArticleId><ArticleId IdType="pubmed">7609046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, et al. . The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. (2007) 1:135&#x2013;45. 10.1016/j.chom.2007.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference><Reference><Citation>Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis. (2013) 7:e2274. 10.1371/journal.pntd.0002274</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002274</ArticleId><ArticleId IdType="pmc">PMC3681624</ArticleId><ArticleId IdType="pubmed">23785536</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol. (1999) 73:783&#x2013;6. 10.1128/JVI.73.1.783-786.1999</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.1.783-786.1999</ArticleId><ArticleId IdType="pmc">PMC103889</ArticleId><ArticleId IdType="pubmed">9847388</ArticleId></ArticleIdList></Reference><Reference><Citation>Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol. (2006) 80:10208&#x2013;17. 10.1128/JVI.00062-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00062-06</ArticleId><ArticleId IdType="pmc">PMC1617308</ArticleId><ArticleId IdType="pubmed">17005698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent S, Tigaud I, Schneider H, Buchholz CJ, Yanagi Y, Gerlier D. Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol. (2002) 76:6121&#x2013;30. 10.1128/JVI.76.12.6121-6130.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.12.6121-6130.2002</ArticleId><ArticleId IdType="pmc">PMC136230</ArticleId><ArticleId IdType="pubmed">12021345</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Despres P, et al. . Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine. (2010) 28:6730&#x2013;9. 10.1016/j.vaccine.2010.07.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.07.073</ArticleId><ArticleId IdType="pubmed">20688034</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. . Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. (2015) 7:307ra154. 10.1126/scitranslmed.aac4227</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac4227</ArticleId><ArticleId IdType="pmc">PMC4926955</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, et al. . STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci USA. (2013) 110:3053&#x2013;58. 10.1073/pnas.1220098110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1220098110</ArticleId><ArticleId IdType="pmc">PMC3581986</ArticleId><ArticleId IdType="pubmed">23391734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. . Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. (2019) 216:2057&#x2013;70. 10.1084/jem.20182295</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182295</ArticleId><ArticleId IdType="pmc">PMC6719432</ArticleId><ArticleId IdType="pubmed">31270247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyos-Bachiloglu R, Chou J, Sodroski CN, Beano A, Bainter W, Angelova M, et al. . A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations. J Clin Invest. (2017) 127:4415&#x2013;20. 10.1172/JCI93486</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI93486</ArticleId><ArticleId IdType="pmc">PMC5707159</ArticleId><ArticleId IdType="pubmed">29106381</ArticleId></ArticleIdList></Reference><Reference><Citation>Rio DC, Ares M, Jr, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. (2010) 2010:pdb.prot5439. 10.1101/pdb.prot5439</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot5439</ArticleId><ArticleId IdType="pubmed">20516177</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, et al. . A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol. (2010) 84:3798&#x2013;3807. 10.1128/JVI.01566-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01566-09</ArticleId><ArticleId IdType="pmc">PMC2849488</ArticleId><ArticleId IdType="pubmed">20130066</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C-H, Liu S-J, Tsai J-P, Li Y-S, Chen M-Y, Liu H-H, et al. . A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. (2009) 11:288&#x2013;95. 10.1016/j.micinf.2008.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2008.12.004</ArticleId><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>McCloskey N, Turner MW, Goldblatt TD. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods. (1997) 205:67&#x2013;72. 10.1016/S0022-1759(97)00059-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(97)00059-8</ArticleId><ArticleId IdType="pubmed">9236916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>